natgillin/translations-raw huggingface dataset:
Consequently, caution should be exercised when Cholestagel is used in patients with these disorders. 
Stoga Cholestagel treba primjenjivati uz oprez u bolesnika s ovim poremećajima.
Printing ink: 
Tinta za označavanje:
Apo B decreased by 12%. 
Vrijednosti apolipoproteina B (Apo B) bile su snižene za 12%.
In comparison, in patients given placebo, LDL-C, Total-C, HDL-C and Apo-B were unchanged, while triglycerides increased 5%. 
Za usporedbu, u bolesnika koji su dobivali placebo, vrijednosti LDL kolesterola, ukupnog kolesterola, HDL kolesterola i Apo B ostale su nepromijenjene, dok su vrijednosti triglicerida porasle za 5%.
During therapy, the cholesterol-lowering diet should be continued, and serum total-C, LDL-C and triglyceride levels should be determined periodically during treatment to confirm favourable initial and adequate long-term responses. 
Tijekom terapije treba nastaviti s dijetom za snižavanje kolesterola te periodički određivati razine ukupnog kolesterola, LDL kolesterola i triglicerida u serumu kako bi se potvrdio povoljan početni i odgovarajući dugoročni odgovor na liječenje.
In a clinical study Cholestagel did not affect the faecal excretion of endogenous (hydrophilic) ursodeoxycholic acid. 
U kliničkom ispitivanju Cholestagel nije utjecao na izlučivanje endogene (hidrofilne) ursodeoksikolne kiseline fecesom.
The location of such potential obstruction, the degree of obstruction and the presence or absence of normal gut motility would determine treatment. 
Terapija se određuje ovisno o mjestu moguće opstrukcije, stupnju opstrukcije te prisutnosti ili odsutnosti normalnog motiliteta crijeva.
No interaction was observed when Cholestagel and pioglitazone were administered simultaneously in healthy volunteers 
Nisu opažene interakcije kod istodobne primjene lijeka Cholestagel i pioglitazona u zdravih dobrovoljaca.
Your doctor should only give you Cholestagel if a diet low in fat and cholesterol did not work well enough on its own. 
Liječnik će Vam propisati Cholestagel jedino u slučaju kada samo dijetom s niskim udjelom masti i kolesterola nije postignut dovoljan učinak.
If your doctor suspects that Cholestagel may have an effect on the absorption of the other medication, you may be advised to take Cholestagel at least 4 hours before or at least 4 hours after taking the other medication. 
Ako liječnik posumnja da bi Cholestagel mogao utjecati na apsorpciju drugih lijekova, možda će Vam preporučiti da Cholestagel uzimate najmanje 4 sata prije ili najmanje 4 sata nakon uzimanja drugog lijeka.
There are no data on the effect of Cholestagel on fertility in humans. 
Plodnost Nema podataka o djelovanju lijeka Cholestagel na plodnost u ljudi.
Very rare (may affect up to 1 in 10,000 people): inflammation of the pancreas. 
Vrlo rijetko (mogu se javiti u manje od 1 na 10 000 osoba): upala gušterače.
In a 6-month dose-response study in patients with primary hypercholesterolaemia receiving 3.8 or 4.5 g Cholestagel daily, a 15 to 18% decrease in LDL-C levels was observed, which was evident within 2 weeks of administration. 
U jednom 6-mjesečnom ispitivanju odgovora na dozu u bolesnika s primarnom hiperkolesterolemijom koji su dobivali 3,8 g ili 4,5 g lijeka Cholestagel na dan, zabilježeno je sniženje razine LDL kolesterola za 15 do 18%, koje je bilo primjetno unutar 2 tjedna primjene.
The mechanism of action for the activity of colesevelam, the active substance in Cholestagel, has been evaluated in several in vitro and in vivo studies. 
Mehanizam djelovanja kolesevelama, djelatne tvari u lijeku Cholestagel, ispitan je u nekoliko ispitivanja in vitro i in vivo.
A major portion of bile acids is then absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. 
Najveći dio žučnih kiselina tad se apsorbira iz crijeva i enterohepatičkom cirkulacijom vraća u jetru.
Manufacturer Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland 
Naziv i adresa proizvođača odgovornog(ih) za puštanje serije lijeka u promet Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska
Hypromellose (E464) Diacetylated monoglycerides 
hipromeloza (E464) diacetilirani monogliceridi
For patients on ciclosporin starting or stopping Cholestagel or patients on Cholestagel with a need to start ciclosporin: Cholestagel reduces the bioavailability of ciclosporin (see also section 4.5). 
Za bolesnike na terapiji ciklosporinom koji započinju ili prekidaju terapiju lijekom Cholestagel ili bolesnike na terapiji lijekom Cholestagel koji moraju početi uzimati ciklosporin: Cholestagel smanjuje bioraspoloživost ciklosporina (vidjeti dio 4.5).
When Cholestagel was co-administered with statins in clinical studies, an expected add-on LDL-C lowering effect was observed, and no unexpected effects were observed. 
Kada je u kliničkim ispitivanjima Cholestagel primjenjivan zajedno sa statinima, opažen je očekivan dodatni učinak na sniženje LDL kolesterola, a nisu primijećeni nikakvi neočekivani učinci.
180 tablets without carton 
180 tableta bez kutije
Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density lipoprotein cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. 
Cholestagel je u kombinaciji s inhibitorom 3-hidroksi-3-metil-glutaril-koenzim A (HMG-CoA) reduktaze (statinom) indiciran kao adjuvantna terapija uz dijetu, kako bi se dodatno smanjile razine lipoproteina male gustoće (LDL kolesterola) u odraslih bolesnika s primarnom hiperkolesterolemijom koja se ne može dovoljno dobro kontrolirati samo statinom.
In the paediatric population, the safety and efficacy of 1.9 or 3.8 g/day Cholestagel was assessed in an 8 week multi-centre, randomised, double-blind, placebo-controlled study in 194 boys and postmenarchal girls, aged 10-17 years, with heterozygous FH on a stable dose of statins (47 patients, 24%) or treatment-naïve to lipid-lowering therapy (147 patients, 76%). 
U pedijatrijskoj je populaciji sigurnost i djelotvornost lijeka Cholestagel u dozama od 1,9 g ili 3,8 g na dan ocijenjena u multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju sa 194 dječaka i djevojčica nakon menarhe, u dobi od 10 do 17 godina, s heterozigotnom obiteljskom hiperkolesterolemijom, koji su uzimali stabilnu dozu statina (47 bolesnika, 24%) ili još nisu bili liječeni lijekovima za snižavanje lipida (147 bolesnika, 76%).
This interaction was also observed when Cholestagel was administered one hour after the oral contraceptive pill. 
Ta je interakcija zabilježena i kada je Cholestagel primijenjen jedan sat nakon uzimanja oralne kontracepcijske tablete.
• Ursodeoxycholic acid (a medicine used to dissolve gallstones or treat specific chronic liver diseases). 
• ursodeoksikolne kiseline (lijeka koji se koristi za rastapanje žučnih kamenaca ili za liječenje određenih kroničnih bolesti jetre).
Uncommon (may affect up to 1 in 100 people): muscle pain, raised levels of liver enzymes in your blood, difficulty in swallowing. 
Manje često (mogu se javiti u manje od 1 na 100 osoba): bolovi u mišićima, povišene vrijednosti jetrenih enzima u krvi, otežano gutanje.
Only constipation and dyspepsia were reported by a higher percentage among those receiving Cholestagel, compared with placebo. 
Samo su konstipacija i dispepsija prijavljene u većem postotku u bolesnika koji su dobivali Cholestagel u usporedbi s onima koji su dobivali placebo.
High density polyethylene bottles with a polypropylene cap without outer carton. 
Bočice od polietilena visoke gustoće s polipropilenskim zatvaračem bez vanjske kutije.
These compensatory effects result in increased clearance of LDL-C from the blood, resulting in decreased serum LDL-C levels. 
Rezultat ovih kompenzacijskih učinaka je povećan klirens LDL kolesterola iz krvi, što dovodi do smanjenja razina LDL kolesterola u serumu.
Multi-centre, randomised, double-blind, placebo-controlled studies in 487 patients demonstrated an additive reduction of 8 to 16% in LDL-C when 2.3 to 3.8 g Cholestagel and a statin (atorvastatin, lovastatin or simvastatin) were administered at the same time. 
Multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja s 487 bolesnika pokazala su dodatno sniženje LDL kolesterola za 8 do 16% kod istodobne primjene lijeka Cholestagel u dozi od 2,3 g do 3,8 g i jednog od statina (atorvastatin, lovastatin ili simvastatin).
• Anti-epileptic medicines (medicines, such as phenytoin, used to treat epilepsy). 
• antiepileptika (lijekova za liječenje epilepsije, npr. fenitoina).
Your liver uses cholesterol from your blood to do this, which lowers the level of cholesterol in your blood. 
Za to jetra koristi kolesterol iz krvi, što snižava njegovu razinu u krvi.
Colesevelam is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. 
Kolesevelam je polimer koji snižava razine lipida, ne apsorbira se i veže žučne kiseline u crijevima i tako sprječava njihovu ponovnu apsorpciju.
Colesevelam binds to glimepiride and reduces glimepiride absorption from the gastrointestinal tract. 
Kolesevelam se veže za glimepirid i smanjuje apsorpciju glimepirida iz probavnog trakta.
The combination of ezetimibe 10 mg and Cholestagel 3.8 g daily therapy in the absence of a statin resulted in a significant combined effect for LDL-C lowering by 32% demonstrating an additional effect of 11% LDL-C lowering with Cholestagel and ezetimibe compared to ezetimibe alone. 
Kombinacija ezetimiba u dozi od 10 mg i lijeka Cholestagel u dozi od 3,8 g na dan, bez statina, rezultirala je značajnim kombiniranim učinkom na sniženje LDL kolesterola za 32%, što znači da je kombinacija lijeka Cholestagel i ezetimiba dodatno snizila vrijednosti LDL kolesterola za 11% u usporedbi s ezetimibom samim.
Package sizes are: 180 tablets (1 X 180) 
Veličine pakiranja su: 180 tableta (1 x 180)
Iron oxide black (E172) Hypromellose (E464) Propylene glycol 
crni željezov oksid (E172) hipromeloza (E464) propilenglikol
Elderly population 
Stariji bolesnici
However no interaction was observed when Cholestagel was administered four hours after the oral contraceptive pill. 
Međutim, interakcija nije zabilježena kada je Cholestagel primijenjen 4 sata nakon uzimanja oralne kontracepcijske tablete.
If you are taking anticoagulant therapy you should consult with your physician to closely monitor anticoagulation levels, as Cholestagel may affect the absorption of vitamin K and therefore interfere with the activity of warfarin. 
Ako uzimate antikoagulantne lijekove, morate se posavjetovati s liječnikom kako bi pažljivo kontrolirao razinu antikoagulacije budući da Cholestagel može utjecati na apsorpciju vitamina
No interaction was observed when glimepiride was taken at least 4 hours before colesevelam. 
Nije opažena interakcija pri uzimanju glimepirida najmanje 4 sata prije kolesevelama.
In these patients, monitoring vitamin A, D and E levels and assessing vitamin K status through the measurement of coagulation parameters is recommended and the vitamins should be supplemented if necessary. 
U tih se bolesnika preporučuje praćenje vrijednosti vitamina A, D i E i procjena statusa vitamina
- Cholestagel may be used together with a statin and the diet low in fat and cholesterol when patients are not appropriately controlled by the statin on its own. 
- Cholestagel se može koristiti zajedno sa statinom i uz dijetu s niskim udjelom masti i kolesterola kada se stanje bolesnika ne može dovoljno dobro kontrolirati samo statinom.
Very common (may affect more than 1 in 10 people): flatulence (wind), constipation. 
Vrlo često (mogu se javiti u više od 1 na 10 osoba): vjetrovi, zatvor.
Very common: Flatulence*, constipation* Common: Vomiting, diarrhoea*, dyspepsia*, abdominal pain, abnormal stools, nausea, abdominal distension 
Često: povraćanje, proljev*, dispepsija*, bol u abdomenu, poremećaj stolice, mučnina, distenzija abdomena Manje često: disfagija
If you stop taking Cholestagel Your cholesterol may increase to the level it was before treatment was started. 
Vrijednosti kolesterola mogu se povisiti na razinu prije početka liječenja.
Before starting therapy with Cholestagel, you should be advised to follow a cholesterol-lowering diet and you should continue this diet during treatment. 
Prije početka liječenja lijekom Cholestagel liječnik Vam mora preporučiti dijetu za snižavanje kolesterola koju morate nastaviti tijekom trajanja terapije.
Not known: Intestinal obstruction*,** Musculoskeletal and connective tissue disorders Uncommon: Myalgia 
Nepoznato: intestinalna opstrukcija*,**
For statin-naïve patients on monotherapy, Cholestagel resulted in a statistically significant LDL-C reduction of 12% at 3.8 g/day and 7% at 1.9 g/day, versus a 1% reduction in the placebo group (see section 4.2). 
U bolesnika koji prethodno nisu uzimali statine, monoterapijom lijekom Cholestagel postignuto je statistički značajno sniženje LDL kolesterola od 12% uz dozu od 3,8 g na dan, odnosnoi 7% uz dozu od 1,9 g na dan, u usporedbi sa sniženjem od 1% u placebo skupini (vidjeti dio 4.2).
Each tablet contains 625 mg colesevelam. 
Jedna tableta sadrži 625 mg kolesevelama.
Cholestagel did not induce any clinically significant reduction in the absorption of vitamins A, D, E or K during clinical studies of up to one year. 
Tijekom kliničkih ispitivanja u trajanju do godine dana Cholestagel nije izazvao klinički značajno smanjenje apsorpcije vitamina A, D, E ili K.
A MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE
The most frequently occurring adverse reactions are flatulence and constipation, found within the gastrointestinal disorders system organ class. 
Sažetak sigurnosnog profila Najčešće nuspojave su flatulencija i konstipacija, koje prema klasifikaciji organskih sustava pripadaju poremećajima probavnog sustava.
6.6 Instructions precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti sukladno nacionalnim propisima.
How to take Cholestagel 
Kako uzimati Cholestagel
The effect of 3.8 g Cholestagel plus 10 mg ezetimibe versus 10 mg ezetimibe alone on LDL-C levels was assessed in a multicentre, randomised, double-blind, placebo-controlled, parallel-group study in 86 patients with primary hypercholesterolaemia over a 6-week treatment period. 
Učinak lijeka Cholestagel od 3,8 g zajedno s 10 mg ezetimiba na vrijednosti LDL kolesterola, u usporedbi s primjenom samo ezetimiba u dozi od 10 mg, ispitan je u multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju s paralelnim skupinama, u 86 bolesnika s primarnom hiperkolesterolemijom tijekom šestotjednog liječenja.
• Anticoagulant therapy (medicines, such as warfarin, used to thin blood). 
• antikoagulantnih lijekova (lijekova za razrjeđivanje krvi, npr. varfarina).
Cholestagel works in your intestinal system by binding bile acids produced by your liver and carrying the bile acids out of your body with your faeces. 
Cholestagel djeluje u probavnom sustavu tako što veže žučne kiseline koje stvara jetra i stolicom ih izlučuje iz tijela.
Before starting therapy with Cholestagel, your physician should make sure that certain conditions do not contribute to your elevated cholesterol levels. 
Prije početka liječenja lijekom Cholestagel Vaš se liječnik mora uvjeriti da Vašim povišenim razinama kolesterola ne pridonose određena stanja ili bolesti.
It is important that you take olmesartan at least 4 hours before you take Cholestagel. 
Važno je da olmesartan uzmete najmanje 4 sata prije uzimanja lijeka Cholestagel.
Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total-cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well-tolerated. 
Cholestagel je u monoterapiji indiciran kao adjuvantna terapija uz dijetu za smanjenje povišenih vrijednosti ukupnog i LDL kolesterola u odraslih bolesnika s primarnom hiperkolesterolemijom u kojih se primjena statina smatra neprikladnom ili ga bolesnici dobro ne podnose.
In an interaction study in healthy volunteers, co-administration of Cholestagel and ciclosporin significantly reduced the AUC0-inf and Cmax of ciclosporin by 34% by 44%, respectively. 
U ispitivanju interakcija u zdravih dobrovoljaca istodobna primjena lijeka Cholestagel i ciklosporina značajno je smanjila AUC0-inf i Cmax ciklosporina: AUC za 34%, a Cmax za 44%.
The LDL-C lowering mechanism of bile acid sequestrants has been previously established as follows: As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7--hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. 
Ranije je utvrđeno da je mehanizam sekvestranata žučne kiseline za snižavanje LDL kolesterola sljedeći: kako se količina žučne kiseline smanjuje, povećava se stvaranje jetrenog enzima kolesterol 7-α-hidroksilaze, zbog čega dolazi do povećanog pretvaranja kolesterola u žučne kiseline.
OUTER CARTON AND BOTTLE LABEL (24, 100 AND 180 TABLETS) WITH CARTON BOTTLE LABEL (180 TABLETS) WITHOUT CARTON 
VANJSKA KUTIJA I NALJEPNICA NA BOČICI (24, 100 I 180 TABLETA)
• Thyroid replacement therapy (medicines, such as thyroxine or levothyroxine, used to treat low thyroid hormone levels) 
• lijekova za nadomještanje hormona štitnjače (lijekova za reguliranje niskih vrijednosti hormona štitnjače, npr. tiroksina ili levotiroksina)
Co-administration of colesevelam and glipizide decreases the exposure of glipizide. 
Istodobna primjena kolesevelama i glipizida smanjuje izloženost glipizida.
High density polyethylene bottles with a polypropylene cap. 
Bočice od polietilena visoke gustoće s polipropilenskim zatvaračem.
The addition of Cholestagel 3.8 g daily to maximally-tolerated statin and ezetimibe therapy was assessed in a multi-centre, randomised, double-blind, placebo-controlled study in 86 patients with familial hypercholesterolaemia. 
Dodavanje lijeka Cholestagel u dozi od 3,8 g na dan u terapiju maksimalnim podnošljivim dozama statina i ezetimiba ocijenjeno je u multicentričnom, randomiziranom, dvostruko slijepom, placebo kontroliranom ispitivanju s paralelnim skupinama, u 86 bolesnika s obiteljskom hiperkolesterolemijom.
The fenofibrate plus Cholestagel group (64 patients) demonstrated a 10% reduction on LDL-C levels versus 2% increase for the fenofibrate group 
U skupini koja je dobivala fenofibrat i Cholestagel (64 bolesnika) zabilježeno je sniženje vrijednosti LDL kolesterola od 10%, u usporedbi s porastom od 2% u skupini koja je dobivala samo fenofibrat (65 bolesnika).
Genzyme Europe B.V. Paasheuvelweg 25, 1105 BP Amsterdam The Netherlands 
Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, Nizozemska.
Cholestagel contains the active substance colesevelam (as hydrochloride). 
Cholestagel sadrži djelatnu tvar kolesevelam (u obliku kolesevelamklorida).
Marketing authorisation holder Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, the Netherlands 
Nositelj odobrenja za stavljanjelijeka u promet Genzyme Europe B.V., Paasheuvelweg 25, 1105 BP Amsterdam, Nizozemska
The incidence of intestinal obstruction is likely to be increased among patients with a history of bowel obstruction or removal. 
Vjerojatna je povećana incidencija intestinalne opstrukcije u bolesnika s crijevnom opstrukcijom ili uklanjanjem crijeva u anamnezi.
When a drug interaction cannot be excluded with a concomitant medicinal product for which minor variations in the therapeutic level would be clinically important, or where no clinical data are available on co-administration, Cholestagel should be administered at least four hours before or at least four hours after the concomitant medication in order to minimize the risk of reduced absorption of the concomitant medication (see section 4.5). 
Ako nije moguće isključiti interakciju s istodobno primijenjenim lijekom za koji bi male varijacije terapijskih razina bile klinički važne, ili ako ne postoje klinički podaci o istodobnoj primjeni, potrebno je Cholestagel uzimati najmanje 4 sata prije ili najmanje 4 sata nakon popratnog lijeka kako bi se što više umanjio rizik od smanjene apsorpcije popratnog lijeka (vidjeti dio 4.5).
Anticoagulant therapy 
Antikoagulantna terapija
Co-administration of colesevelam and metformin extended-release (ER) tablets increases the exposure of metformin. 
Antidijabetici Istodobna primjena kolesevelama i tableta metformina s produženim oslobađanjem povećava izloženost metformina.
It should be noted that stopping Cholestagel therapy will result in increased ciclosporin blood concentrations. 
Cholestagel rezultirati povišenjem koncentracije ciklosporina u krvi.
Patients starting on Cholestagel already taking ciclosporin should have their blood concentrations monitored prior to combination therapy and frequently monitored immediately starting co-therapy with the ciclosporin dose adjusted accordingly. 
U bolesnika koji započinju terapiju lijekom Cholestagel a već uzimaju ciklosporin, treba odrediti koncentraciju ciklosporina u krvi prije početka kombinirane terapije i često je kontrolirati neposredno nakon započinjanja kombinirane terapije te sukladno nalazima prilagođavati dozu ciklosporina.
- The active substance is colesevelam (as hydrochloride). 
- Djelatna tvar je kolesevelam (u obliku kolesevelamklorida).
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland 
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje lijeka u promet.
In general 
Općenito
The safety of Cholestagel has not been established in breast-feeding women. 
Sigurnost lijeka Cholestagel u dojilja nije ustanovljena.
How to store Cholestagel 
Kako čuvati Cholestagel
Do not take Cholestagel: - if you are allergic to colesevelam or to any of the other ingredients of this medicine (listed in section 6) - if you have a blockage in your intestines or bile ducts (tubes that carry bile) 
- ako ste alergični na kolesevelam ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
The recommended dose for Cholestagel, when used with a statin or ezetimibe or both together, is 4 to 6 tablets a day by mouth. 
Preporučena doza lijeka Cholestagel u kombinaciji sa statinom ili ezetimibom ili oba ova lijeka iznosi 4 do 6 tableta na dan, a uzima se kroz usta.
- Cholestagel may be prescribed on its own in addition to a diet low in fat and cholesterol when treatment with a statin (a class of cholesterol-lowering medicines that work in the liver) is inappropriate or not well tolerated. 
- Cholestagel se može propisati kao jedini lijek uz dijetu s niskim udjelom masti i kolesterola kada liječenje statinom (skupina lijekova za snižavanje kolesterola koji djeluje u jetri) nije primjereno ili ga bolesnik ne podnosi.
Package sizes are: 24 tablets (1 X 24) 
Veličine pakiranja su: 24 tablete (1 x 24) 100 tableta (2 x 50)
Cholestagel has not been compared directly to other bile acid sequestrants in clinical trials. 
U kliničkim ispitivanjima Cholestagel nije izravno uspoređivan s drugim sekvestrantima žučne kiseline.
It is important that you take glimepiride and glipizide at least 4 hours before you take Cholestagel. 
Važno je da glimepirid i glipizid uzmete najmanje 4 sata prije uzimanja lijeka Cholestagel.
Anticoagulant therapy should be monitored closely in patients receiving warfarin or similar agents, since bile acid sequestrants, like Cholestagel, have been shown to reduce absorption of vitamin K and therefore interfere with warfarin's anticoagulant effect. 
Antikoagulantnu terapiju treba pomno nadzirati u bolesnika koji dobivaju varfarin ili slične lijekove jer se pokazalo da sekvestranti žučne kiseline, poput lijeka Cholestagel, smanjuju apsorpciju vitamina
Co-administration of colesevelam and olmesartan decreases the exposure of olmesartan. 
Istodobna primjena kolesevelama i olmesartana smanjuje izloženost olmesartana.